Literature DB >> 22497640

1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens.

Norbert Grzasko, Marek Hus, Sylwia Chocholska, Andrzej Pluta, Roman Hajek, Anna Dmoszynska.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22497640     DOI： 10.3109/10428194.2012.684349

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  2 in total

1.  Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.

Authors:  Yu-Tong Wang; Li Bao; Bin Chu; Xiao-Huan Chen; Min-Qiu Lu; Lei Shi; Shan Gao; Li-Juan Fang; Qiu-Qing Xiang; Yue-Hua Ding
Journal:  J Clin Lab Anal       Date:  2022-03-30       Impact factor: 3.124

2.  Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.

Authors:  Pratibha S Kadam Amare; Hemani Jain; Shraddha Nikalje; Manju Sengar; Hari Menon; Nitin Inamdar; P G Subramanian; Sumeet Gujral; Tanuja Shet; Sridhar Epari; Reena Nair
Journal:  Indian J Med Res       Date:  2016-10       Impact factor: 2.375
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.